About the Study : In this randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer, stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT for disease-free survival at 3 years. SBRT was associated with better bowel-related quality of life, but cancer control was not improved.
Reporting Resource :
Visit JAMA+ Trials for JAMA Network highlights curated by Editor in Chief Alison Huang, MD, MAS. Dive into Dr Huang's " Theme of the Month ," stay up to date with our resources page , and search recently published trials by topic .
Corresponding Author : Rodney J. Ellis, MD, University South Florida, Two Tampa General Cir, Tampa, FL 33606 ( rellis@tgh.org ).
10.1001/jama.2026.12627
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note : Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA